What’s new in stroke prevention and treatment

References

• Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses. Arch. Neurol. 57, 326–332 (2000).
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, 234S–264S (2004).
   PubMed Web of Science ®Google Scholar
• Fung TT, Stampfer MJ, Manson JE, Rexrode KM, Willett WC, Hu FB. Prospective study of major dietary patterns and stroke risk in women. Stroke 35, 2014–2019 (2004).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up to date meta-analysis. Stroke 35, 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 64, 817–820 (2005).
   PubMed Web of Science ®Google Scholar
• Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284, 2901–2906 (2000).
   PubMed Web of Science ®Google Scholar
• Halliday A, Mansfield A, Marro J et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363, 1491–1502 (2004).
   PubMed Web of Science ®Google Scholar
• Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomaticcarotid artery stenosis. JAMA 273, 1421–1428 (1995).
   PubMed Web of Science ®Google Scholar
• Hacke W, Donnan G, Fieschi C. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363, 768–774 (2004).
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Sandercock SP, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 34, 1437–1442 (2003).
   PubMed Web of Science ®Google Scholar
• Ribo M, Molina CA, Rovira A et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36, 602–606 (2005).
   PubMed Web of Science ®Google Scholar
• Rother J, Schellinger PD, Gass A et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 h. Stroke 33, 2438–2445 (2002).
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36, 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Alexandrov AV, Molina CA, Grotta JC et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 351, 2170–2178 (2004).
   PubMed Web of Science ®Google Scholar
• Daffertshofer M, Gass A, Ringleb P et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischaemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a Phase II clinical trial. Stroke 36, 1441–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Beletsky V, Nadareishvili Z, Lynch J, Shuaib A, Woolfenden A, Norris JW. Cervical arterial dissection: time for a therapeutic trial? Stroke 34, 2856–2860 (2003).
   PubMed Web of Science ®Google Scholar
• Georgiadis D, Lanczik O, Schwab S et al. IV thrombolysis in patients with acute stroke due to spontaneous carotid dissection. Neurology 64, 1612–1614 (2005).
   PubMed Web of Science ®Google Scholar
• Abciximab Emergent StrokeTreatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase 2 trial. Stroke 36, 880–890 (2005).
   PubMed Web of Science ®Google Scholar
• Wojner-Alexandrov AW, Garami Z, Chernyshev OY, Alexandrov AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 64, 1354–1357 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke 33, 497–501 (2002).
   PubMed Web of Science ®Google Scholar
• Dennis MS, Lewis SC, Warlow C. Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomised controlled trial. Lancet 365, 755–763 (2005).
   PubMed Web of Science ®Google Scholar
• Dennis MS, Lewis SC, Warlow C. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet 365, 764–772 (2005).
   PubMed Web of Science ®Google Scholar
• Aslanyan S, Weir CJ, Johnston SC, Lees KR. Poststroke neurological improvement within 7 days is associated with subsequent deterioration. Stroke 35, 2165–2170 (2004).
   PubMed Web of Science ®Google Scholar
• Johnston SC LE, Hansen MD, Adams HP Jr. Early recovery after cerebral ischaemia risk of subsequent neurological deterioration. Ann. Neurol. 54, 439–444 (2003).
   PubMed Web of Science ®Google Scholar
• Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC. Neurologic worsening during the acute phase of ischemic stroke. Arch. Neurol. 62, 393–397 (2005).
   PubMedGoogle Scholar
• Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352, 1305–1316 (2005).
   PubMed Web of Science ®Google Scholar
• Executive Steering Committeeon behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691–1698 (2003).
   PubMed Web of Science ®Google Scholar
• Albers G, Diener HC, Frison L et al. Ximelagatran vs. warfarin for stroke prevention in patients with nonvavular atrial fibrillation. JAMA 293, 690–698 (2005).
   PubMed Web of Science ®Google Scholar
• Leonardi-Bee J, Bath PM, Bousser MG et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 36, 162–168 (2005).
   PubMed Web of Science ®Google Scholar
• Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1–13 (1996).
   PubMed Web of Science ®Google Scholar
• Wolf PA, D’Agostino B, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 22, 312–318 (1991).
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Brass LM et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischaemia and nondisabling ischemic stroke. Stroke 31, 456–462 (2000).
   PubMed Web of Science ®Google Scholar
• Sacco RL, Sivenius J, Diener HC. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch. Neurol. 62, 403–408 (2005).
   PubMedGoogle Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin. Pharmacother. 6, 755–764 (2005).
   PubMed Web of Science ®Google Scholar
• Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 1, 19–26 (2005).
   Google Scholar
• Diener H, Bogousslavsky J, Brass L et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 364, 331–334 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Yadav JS, Wholey MH, Kuntz RE et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. 351, 1493–1501 (2004).
   PubMed Web of Science ®Google Scholar
• Ringleb P, Kunze A, Allenberg J et al. The stent-supported percutaneous angioplasty of the carotid artery vs. endarterectomy trial (SPACE). Cerebrovasc. Dis. 18, 66–68 (2004).
   PubMed Web of Science ®Google Scholar
• Theiss W, Hermanek P, Mathias K et al. Pro-CAS: a prospective registry of carotid angioplasty and stenting. Stroke 35, 2134–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Kastrup A, Groschel K, Schulz JB, Nagele T, Ernemann U. Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. Stroke 36, 787–791 (2005).
   PubMed Web of Science ®Google Scholar
• Hill MD, Shrive FM, Kennedy J, Feasby TE, Ghali WA. Simultaneous carotid endarterectomy and coronary artery bypass surgery in Canada. Neurology 64, 1435–1437 (2005).
   PubMed Web of Science ®Google Scholar
• Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really ‘shut the door?’ A prospective study with transcranial Doppler. Stroke 35, 2140–2144 (2004).
   PubMed Web of Science ®Google Scholar
• Carota A, Berney A, Aybek S et al. A prospective study of predictors of poststroke depression. Neurology 64, 428–433 (2005).
   PubMed Web of Science ®Google Scholar
• Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 36, 1098–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Mendelow A, Gregson B, Fernandes H et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365, 387–397 (2005).
   PubMed Web of Science ®Google Scholar
• Mayer SA, Brun NC, Begtrup K et al. Recombinant activated Factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. 352, 777–785 (2005).
   PubMed Web of Science ®Google Scholar
• Mayer SA, Brun NC, Broderick J et al. Safety and feasibility of recombinant Factor VIIa for acute intracerebral hemorrhage. Stroke 36, 74–79 (2005).
   PubMed Web of Science ®Google Scholar
• Radziszewska B, Hart RG, Wolf PA, D’Agostino RB Sr, Cutler JA. Clinical research in primary stroke prevention: needs, opportunities, and challenges. Neuroepidemiology 25, 91–104 (2005).
   PubMed Web of Science ®Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
   PubMed Web of Science ®Google Scholar
• Felten RP, Ogden NR, Pena C, Provost MC, Schlosser MJ, Witten CM. The Food and Drug Administration medical device review process: clearance of a clot retriever for use in ischemic stroke. Stroke 36, 404–406 (2005).
   PubMed Web of Science ®Google Scholar
• Gustafsson D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 254, 322–334 (2003).
   PubMed Web of Science ®Google Scholar